| Chapter title |
Antiangiogenic strategies in pancreatic cancer.
|
|---|---|
| Chapter number | 14 |
| Book title |
Pancreatic Cancer
|
| Published in |
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 2008
|
| DOI | 10.1007/978-3-540-71279-4_14 |
| Pubmed ID | |
| Book ISBNs |
978-3-54-071266-4, 978-3-54-071279-4
|
| Authors |
Hanno Riess, Riess, Hanno |
| Abstract |
Since the introduction of gemcitabine in the treatment of pancreatic cancer, progress in the use of combination chemotherapies has been very limited. Of the different novel options, antiangiogenic treatment strategies are among those being intensively studied in preclinical and clinical settings of adenocarcinoma of the pancreas. Phase I and limited-size phase II studies using drugs with antiangiogenic properties have reported encouraging results. Overall, the results of phase III studies with some metalloprotease inhibitors and bevacizumab have so far failed to demonstrate a survival benefit for these drugs. Further investigations that will take into account the heterogeneity of pancreatic cancer are warranted using these or other antiangiogenic active substances. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 7 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 2 | 29% |
| Professor | 1 | 14% |
| Student > Bachelor | 1 | 14% |
| Student > Master | 1 | 14% |
| Researcher | 1 | 14% |
| Other | 0 | 0% |
| Unknown | 1 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 57% |
| Agricultural and Biological Sciences | 1 | 14% |
| Engineering | 1 | 14% |
| Unknown | 1 | 14% |